Heron Therapeutics, Inc. (HRTX) Financials

HRTX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 222.5 million 256.5 million
2023-09-30 229.2 million 257.0 million
2023-06-30 201.2 million 240.5 million
2023-03-31 220.9 million 232.3 million

HRTX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 2.2 million 4.3 million
2023-09-30 -10.0 million 6.7 million
2023-06-30 -27.4 million 13.9 million
2023-03-31 -25.1 million 7.9 million

HRTX Net Income

No data available :(

HRTX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 80.4 million - 5.9 million
2023-09-30 77.4 million - 6.5 million
2023-06-30 33.2 million 149.4 million 6.7 million
2023-03-31 60.0 million 149.3 million 7.6 million

HRTX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 150.3 million
2023-09-30 145.0 million
2023-06-30 119.7 million
2023-03-31 119.2 million

HRTX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 250000 11.0 million 11.3 million 12.3 million
2023-09-30 793000 13.6 million 11.6 million 13.0 million
2023-06-30 278000 17.6 million 15.2 million 21.2 million
2023-03-31 224000 13.8 million 10.9 million 21.2 million

HRTX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 34.2 million 9.9 million
2023-09-30 31.4 million 18.2 million
2023-06-30 31.8 million 20.2 million
2023-03-31 29.6 million 16.9 million

HRTX

Price: $2.55

52 week price:
0.50
3.22

Earnings Per Share: -0.80 USD

P/E Ratio: -2.99

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 4.0 million

Ebitda: -40.9 million

Market Capitalization: 437.5 million

Links: